Research has identified the overexpression of SETDB1 in many malignancies, such as glioblastoma, melanoma, prostate cancer, and breast cancer (BRC), which was linked to cancer cell division as well as metastasis [23, 26, 38]. Here, SETDB1 is linked to prostate cancer.